Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. (CELZ) filed a Form 8-K on December 19, 2024, reporting corporate governance actions taken on December 19 and December 20, 2024. The company is incorporated in Nevada and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
- Authorized Share Increase: Stockholders approved an amendment to the Articles of Incorporation increasing authorized common stock from 5,000,000 to 25,000,000 shares.
- Preferred Stock Withdrawal: The company filed certificates to withdraw the designations for Series A and Series B Preferred Stock. No shares of these series were outstanding at the time of filing.
- Warrant Exercise Approval: Stockholders approved the full exercise of warrants to purchase 837,104 shares of common stock issued in a private placement on October 23, 2024.
Guidance, Outlook, and Voting Results
The filing details the results of a Special Meeting of Stockholders held on December 19, 2024. A quorum was established with 1,107,141 shares of common stock and one share of Series B Preferred Stock present (61.3% of outstanding common stock).
Voting Results
- Proposal I (Share Increase): Approved with 64,980,590 votes "For" versus 35,802,212 "Against". The Series B Preferred Stock held 100,000,000 votes on this proposal, cast proportionally to common stock votes.
- Proposal II (Warrant Exercise): Approved with 301,878 votes "For" versus 105,960 "Against".
The filing does not provide management commentary on future financial guidance, risks, or contingencies beyond the procedural details of the stockholder vote.
Investor Verification Checklist
- Verify the impact of the 20,000,000 share increase on potential future dilution.
- Confirm the execution of the 837,104 warrant exercises and the resulting cash inflow or share issuance.
- Review the definitive proxy statement filed on November 4, 2024, for detailed rationale behind the proposals.
- Check subsequent filings for the actual issuance of shares resulting from the approved warrant exercise.